EI
EGRX

EAM Investors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

EAM Investors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-37,106
Closed -$2.94M – 381
2016
Q4 		$2.94M Buy
+37,106
New +$2.7M 0.39% 115
2016
Q1 		– Sell
-48,624
Closed -$4.31M – 354
2015
Q4 		$4.31M Buy
48,624
+6,780
+16% +$535K 0.56% 31
2015
Q3 		$3.1M Sell
41,844
-35,758
-46% -$2.97M 0.49% 51
2015
Q2 		$6.28M Sell
77,602
-77,132
-50% -$5.02M 0.73% 6
2015
Q1 		$6.48M Buy
+154,734
New +$4.39M 0.75% 3

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

EAM Investors's EGRX Position: Q1 2017 in Review

EAM Investors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2017, closing a stake of 37,106 shares — an estimated $2.94M sold.

EAM Investors first reported a position in EGRX in Q1 2015 and held it in 5 quarters. The position peaked at $6.48M in Q1 2015. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

  • EAM Investors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • EAM Investors sold 37,106 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $2.94M.
  • EAM Investors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 5 quarters.
  • EAM Investors's Eagle Pharmaceuticals, Inc. position peaked at $6.48M in Q1 2015.
  • 147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on EAM Investors's 13F filing for Q1 2017, filed 10 May 2017.